|Other names||Testosterone 17β-trimethylsilyl ether; Testosterone O-trimethylsilyl ether; 17β-Trimethylsilyltestosterone; O-Trimethylsilyltestosterone; 17β-(trimethylsiloxy)androst-4-en-3-one; SC-16148; NSC-95147|
|By mouth, intramuscular injection, subcutaneous injection|
|Chemical and physical data|
|Molar mass||360.613 g/mol g·mol−1|
|3D model (JSmol)|
Silandrone (INN, USAN) (developmental code names SC-16148, NSC-95147), also known as testosterone 17β-trimethylsilyl ether or 17β-trimethylsilyltestosterone, as well as 17β-(trimethylsiloxy)androst-4-en-3-one, is a synthetic anabolic-androgenic steroid (AAS) and an androgen ether – specifically, the 17β-trimethylsilyl ether of testosterone – which was developed by the G. D. Searle & Company in the 1960s but was never marketed. It has a very long duration of action when given via subcutaneous or intramuscular injection as well as, notably, significantly greater potency than that of testosterone propionate. In addition, it is notable that silandrone, unlike testosterone and most esters of testosterone like testosterone propionate, is orally active.
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|